Theranexus optimizes its cash flow and extends its financial horizon

Theranexus, a French biopharmaceutical company, has released a statement of its cash flow and financing horizon. As of December 12, 2024, available cash stands at €1.5 million, down from September. However, expected cash receipts are expected to increase this amount to €4.8 million.

These funds will come in particular from a licensing agreement with Exeltis and amounts paid by Bpifrance. Theranexus has also obtained a restructuring of its debt with a deferral of repayment until March 2026.

Thanks to these measures, the company's cash horizon is now extended until the end of March 2026. Theranexus plans to explore various partnerships to develop its project in Batten disease.